MK-677 Long-Term Safety and Sustained IGF-1 Elevation

MK-677

72.9% IGF-1 rise

MK-677 at 25 mg daily sustained a 72.9% increase in serum IGF-1 at 12 months in the largest controlled trial, the 563-patient Alzheimer's study.

Sevigny et al., Neurology, 2008

Sevigny et al., Neurology, 2008

View as image

MK-677 (ibutamoren) does something that most peptide interventions cannot: it maintains elevated growth hormone and IGF-1 levels for months to years through daily oral dosing. The 563-patient Alzheimer's disease trial showed IGF-1 remained 72.9% above baseline at 12 months of continuous use.^[1] The Nass 2-year trial confirmed that this elevation persists through year two.^[2] This sustained IGF-1 elevation is simultaneously the therapeutic premise and the primary safety concern. For an overview of MK-677's mechanism and pharmacology, see the pillar article.

How sustained is the IGF-1 elevation?

The pharmacological question matters: does MK-677's effect on IGF-1 persist, or does tachyphylaxis develop?

Chapman's 1996 study showed IGF-1 rising from 141 to 219 micrograms/L at 2 weeks and 265 at 4 weeks with 25 mg daily, suggesting a progressive increase during the first month.^[3] The Sevigny Alzheimer's trial confirmed that elevation was maintained, with IGF-1 levels 72.9% above baseline at 12 months and showing no sign of attenuation.^[1] The Nass 2-year study confirmed persistence through the second year.^[2]

Importantly, while IGF-1 elevation is sustained, the GH peak response shows some attenuation. Svensson's 1998 study noted that GH peaks after the initial MK-677 dose were significantly greater than after multiple doses, suggesting partial desensitization of the GH release mechanism.^[4] This occurs because MK-677 works through ghrelin receptor (GHS-R1a) activation, and receptor internalization and downregulation are expected with chronic stimulation.

The paradox: GH peaks diminish but IGF-1 stays elevated. This likely reflects the fact that even reduced GH pulsatility is sufficient to maintain hepatic IGF-1 production above baseline. The liver integrates cumulative GH exposure over time, so even modestly elevated average GH produces sustained IGF-1 output.

For anyone using MK-677 continuously, this means IGF-1 will remain elevated for as long as the compound is taken. There is no plateau where the body "adjusts" and IGF-1 normalizes. The feedback regulation noted in the Smith 2023 review prevents IGF-1 from rising indefinitely (negative feedback limits GH peaks), but it does not return IGF-1 to pre-treatment levels.^[5]

The IGF-1 and cancer risk question

This is the most serious unknown in MK-677 long-term safety. IGF-1 is a growth factor. Elevated circulating IGF-1 has been associated in epidemiological studies with increased risk of several cancers.

A 2004 Lancet meta-regression analysis pooling data from multiple prospective studies found that high IGF-1 concentrations were associated with increased risk of prostate cancer (odds ratio 1.49, comparing the 75th to 25th percentile) and premenopausal breast cancer (odds ratio 1.65). A large UK Biobank cohort study of over 395,000 participants confirmed positive associations between circulating IGF-1 and colorectal cancer risk (hazard ratio 1.07 per standard deviation increase), with similar trends for prostate and breast cancer.

MK-677 raises IGF-1 by 40-73% across clinical trials. The question is whether this pharmacologically induced elevation carries the same risk as naturally high IGF-1 levels. No MK-677 trial has been designed to answer this.

The Sevigny Alzheimer's trial, the largest at 563 patients for 12 months, reported no increased cancer incidence in the MK-677 group.^[1] But the trial was far too small and too short to detect a cancer signal. Most cancers take years to decades to develop from initiation to clinical detection. A 12-month trial in 563 patients would need an extraordinarily large effect size (much larger than the epidemiological associations suggest) to produce a detectable signal.

The IGF-1 elevation and cancer risk article in this cluster covers the theoretical and epidemiological evidence in full. The bottom line for MK-677 specifically: the cancer risk from sustained 73% IGF-1 elevation is plausible based on epidemiology, biologically consistent with IGF-1's role as a growth factor, but unproven and unquantified because no trial has been large or long enough to measure it.

Insulin resistance: the proven metabolic cost

Unlike cancer risk (theoretical), MK-677's effect on glucose metabolism is well-documented and consistent across trials.

The Nass 2-year trial showed fasting glucose increasing by 0.3 mmol/L (approximately 5 mg/dL) with MK-677 versus placebo (P = 0.015), and insulin sensitivity decreased.^[2] This was persistent throughout the 2-year treatment period with no sign of resolving.

Svensson's 8-week study in 24 obese men demonstrated impaired oral glucose tolerance at both 2 and 8 weeks despite normal fasting glucose.^[4] This is a critical detail: standard fasting blood glucose testing would not detect the deterioration. An oral glucose tolerance test (OGTT) was required to reveal it. Users monitoring only fasting glucose may falsely believe their glucose metabolism is unaffected.

The mechanism is pharmacologically predictable. Growth hormone is a counter-regulatory hormone that opposes insulin action. GH promotes lipolysis and diverts glucose away from muscle uptake, increasing hepatic glucose output. IGF-1 has insulin-sensitizing properties that partially offset this, but in MK-677 trials the GH-mediated insulin resistance dominates the net effect.

The Sigalos 2018 review summarized the concern: "development of insulin resistance is of concern because it predisposes a patient to diabetes mellitus and vascular disease."^[6] For individuals already carrying metabolic risk factors (obesity, family history of diabetes, elevated HbA1c), MK-677 pushes glucose metabolism further in an unfavorable direction.

For a detailed breakdown of this specific side effect, see MK-677 side effects: water retention, insulin resistance, and hunger.

Cortisol elevation: persistent or transient?

MK-677 gently stimulates the hypothalamic-pituitary-adrenal axis. The data on whether this is clinically meaningful is contradictory.

The Nass 2-year trial reported cortisol levels increasing by 47 nmol/L (approximately 1.7 mcg/dL) in MK-677 recipients (P = 0.020).^[2] This was a persistent finding through 2 years.

In contrast, Svensson's study found that cortisol elevation was transient: at 2 and 8 weeks, serum and urinary cortisol concentrations were not significantly different from placebo, despite being elevated acutely after the first doses.^[4]

The discrepancy may reflect study duration (2 years vs 8 weeks), population differences (healthy elderly vs obese middle-aged), or measurement methodology. A 47 nmol/L cortisol increase is modest; it does not approach the levels seen in Cushing's syndrome or chronic corticosteroid therapy. But in the context of chronic use over years, even modest cortisol elevation could contribute to bone density loss, immune suppression, or central adiposity.

The cardiovascular signals

Two cardiovascular concerns have emerged from MK-677 trials.

Fluid retention is predictable from GH physiology. Growth hormone promotes sodium and water reabsorption in the kidney. The Nass trial reported transient lower-extremity edema in the MK-677 group.^[2] In healthy adults, this resolved without intervention. In frail elderly hip fracture patients, the consequences were more severe.

Congestive heart failure was the signal that terminated the Adunsky 2011 trial.^[7] Four of 62 MK-677 patients (6.5%) developed CHF versus 1 of 61 placebo patients (1.7%). The population was elderly (mean age approximately 80), post-surgical, and likely had pre-existing cardiovascular compromise. Whether this signal applies to healthier, younger populations is unknown. The GH secretagogue risk profiles article covers this in detail.

Murphy's 1998 study of MK-677 in young, healthy, calorically restricted men showed no cardiovascular adverse events over 7 days, though the duration was far too short to be informative.^[8] The study did demonstrate that MK-677 reversed diet-induced nitrogen wasting, confirming its anti-catabolic properties even in caloric deficit.

What we know after 30 years of MK-677 research

MK-677 has been studied in human clinical trials since 1996. In those 30 years:

Established: MK-677 reliably raises GH and IGF-1 to youthful levels in older adults. The effect persists for at least 2 years without complete tachyphylaxis. It increases DEXA-measured fat-free mass by approximately 1 kg per year. It impairs glucose metabolism across every population studied, from healthy elderly to obese younger men.

Observed in vulnerable populations: CHF in frail elderly hip fracture patients. Edema in healthy elderly adults (transient). Cortisol elevation (persistent in the longest trial).

Never tested: Cancer incidence with chronic use. Cardiovascular mortality. Outcomes in middle-aged recreational users. Effects of combined use with other compounds. Whether discontinuation after years of use produces rebound effects.

The Smith 2023 review framed the paradox clearly: GH secretagogues can restore GH secretion to youthful levels, but the question of whether this is desirable over the long term has not been answered.^[5] Youthful GH levels are associated with youthful anabolism, but also with youthful cell proliferation rates. Whether the benefits of the former outweigh the risks of the latter over 5, 10, or 20 years of use is unknown.

The broader evidence gap for long-term GH peptide safety explains why this question may never be answered through traditional clinical trials. The funding, regulatory framework, and commercial incentive to run a 10-year MK-677 safety trial do not exist.

The Bottom Line

MK-677's sustained 73% IGF-1 elevation is both its purpose and its primary risk. The compound reliably restores youthful GH-IGF-1 signaling in older adults, but this restoration carries documented metabolic costs (insulin resistance, cortisol elevation) and theoretical oncological risk (sustained growth factor elevation in a population whose cancer risk increases with age). The 2-year safety data is reassuring for acute and medium-term tolerability in healthy elderly adults, but cannot address the questions that matter most: cancer, cardiovascular mortality, and the consequences of decade-long use in the middle-aged population that represents the majority of real-world users.

Frequently Asked Questions

How long does MK-677 keep IGF-1 elevated?

MK-677 sustains IGF-1 elevation for as long as you take it. The Sevigny Alzheimer's trial showed a 72.9% IGF-1 increase at 12 months with no sign of declining. The Nass 2-year study confirmed persistence through year two. While GH peak response shows some attenuation over time, IGF-1 remains elevated because even reduced GH pulsatility is sufficient to maintain hepatic IGF-1 production.

Does MK-677 cause cancer?

No MK-677 trial has detected cancer, but no trial has been large or long enough to evaluate cancer risk. MK-677 raises IGF-1 by 40-73%, and epidemiological data links high IGF-1 to increased prostate cancer risk (49% higher) and premenopausal breast cancer risk (65% higher). Whether pharmacologically elevated IGF-1 carries the same risk as naturally high levels is unproven.

Is MK-677 safe for long-term use?

The longest controlled data is 2 years in 65 healthy older adults. It showed sustained IGF-1 elevation and fat-free mass gains but persistent insulin resistance and cortisol elevation. A hip fracture trial was stopped early due to congestive heart failure in 6.5% of patients. No data exists beyond 2 years, and cancer risk from chronic IGF-1 elevation has never been evaluated.

Does MK-677 affect blood sugar?

Yes. Every MK-677 trial shows impaired glucose metabolism. The 2-year Nass trial found fasting glucose increasing 0.3 mmol/L with persistent insulin resistance. Svensson's study showed impaired oral glucose tolerance even when fasting glucose appeared normal. Standard fasting blood work may not reveal the full extent of glucose metabolism disruption.

Does MK-677 stop working over time?

GH peaks diminish modestly with chronic use due to receptor desensitization, but IGF-1 elevation is sustained. The Sevigny trial showed 72.9% IGF-1 increase at 12 months. The anabolic effect (measured as fat-free mass gain) also persists through at least 2 years. MK-677 does not "stop working" in the sense of losing its IGF-1 elevating effect, though the initial GH surge becomes less pronounced.

Is MK-677 safe for the heart?

MK-677 causes fluid retention through GH-mediated sodium and water reabsorption. In healthy older adults, this manifests as mild transient edema. In frail elderly hip fracture patients, 6.5% developed congestive heart failure on MK-677 versus 1.7% on placebo. No cardiovascular safety data exists for middle-aged users, and no long-term cardiovascular outcome trial has been conducted.